Another FDA-approved targeted cancer drug, sunitinib, may be associated with cardiac toxicity, report researchers at Children’s Hospital Boston, Dana-Farber Cancer Institute, and Thomas Jefferson University. Sunitinib is one of several new “smart” cancer drugs called tyrosine kinase inhibitors that targets specific signaling molecules inside cancer cells that aid cancer spread, and was originally thought to be relatively free of cardiac side effects.